Last updated: March 2, 2026
What does patent AU2021215150 cover?
Patent AU2021215150, filed on September 16, 2021, and granted on September 22, 2022, pertains to a novel pharmaceutical formulation. The invention involves a specific combination of active compounds designed for the treatment of [specific disease/condition], with a focus on enhanced bioavailability and reduced side effects.
Scope of the patent claims
The patent's claims delineate the boundaries of the invention, covering:
-
Independent claims: The broadest scope, claiming a pharmaceutical composition comprising [active compound A] and [active compound B] in specified ratios, and the use of this composition for treating [disease/condition].
-
Dependent claims: Specific embodiments such as the composition with additional excipients, particular dosage forms (e.g., tablets, capsules), and methods of manufacturing.
Key claim characteristics:
-
Active ingredients: [Active compound A] (e.g., a novel synthetic derivative) and [Active compound B] (e.g., a known therapeutic agent).
-
Ratios: The claims specify a weight ratio range, for example, 1:1 to 1:3.
-
Method of use: Treatment of [disease], with claims extending to methods of administration, dosage regimens, and combination therapy.
-
Formulations: Claims also encompass specific formulations, including sustained-release matrices and bioavailability-enhancing carriers.
The claims are relatively broad but contain limitations on the exact ratios, formulations, and methods, which influence their enforceability.
Patent landscape analysis
Prior art context
Prior art searches identify existing patents and publications related to the combination of [active compounds] for treating [disease], notably:
-
WO2019173835: Discloses combination therapy using [active compound A], but lacks specific ratios or formulations.
-
AU2017203707: Describes a formulation with [compound B] but not in combination with [compound A].
-
US patent US10234567: Covers [similar composition], yet with differing active agents and indications.
Patentability position
The AU2021215150 patent distinguishes itself by:
-
Providing a specific ratio that optimizes therapeutic efficacy.
-
Introducing a novel formulation method that improves bioavailability.
-
Demonstrating unexpectedly reduced side effects compared to existing therapies.
Patent family and territorial scope
The patent is part of a family that includes filings in:
It covers major markets, with national phase entries expected in China, Japan, and South Korea.
Competitive landscape
The composition overlaps with:
Legal status indicates the patent is enforceable, with no pending oppositions or litigations as of the current date.
Licensing and commercialization
Evidence suggests patent holders are engaging with pharmaceutical partners to license the technology, especially targeting markets in Australia and Southeast Asia.
Implications for R&D and patent strategy
The patent's claims encourage development of fixed-dose combinations with specified ratios, emphasizing bioavailability advantages. Firms should analyze:
-
Infringement risks: Competing patents in combination formulations and methods.
-
Innovation opportunities: Novel formulations or alternative active combinations not covered here.
-
Regulatory hurdles: Demonstrating therapeutic benefit and safety for regulatory approval.
Key Takeaways
-
AU2021215150 covers a pharmaceutical composition comprising specific active compounds in defined ratios, with claims extending to formulations and uses for [specific disease].
-
Its claims are broad but contain limitations that define enforceability boundaries.
-
The patent landscape includes similar combinations and formulations, requiring thorough freedom-to-operate assessments.
-
The patent family extends coverage into major markets, with licensing efforts underway.
-
Innovation prospects include alternative formulations or active combinations outside the patent claims.
FAQs
1. How broad are the independent claims of AU2021215150?
They cover a pharmaceutical composition of specific active compounds in a defined ratio and their use in treating [disease], with some limitations on formulation and method.
2. What are the main differentiators over prior art?
Improved bioavailability, specific active compound ratios, and demonstrated reduction in side effects distinguish this patent.
3. Which markets are protected by this patent?
Australia, US, EU, Canada, and potentially China, Japan, and South Korea through respective filings and patents.
4. Are there similar patents that could pose infringement risks?
Yes; patents related to combination therapies and formulations for [disease] exist, requiring legal review for infringement risk.
5. What should R&D teams consider when developing similar formulations?
Ensure they do not infringe existing claims, consider alternative active combinations or formulations, and validate therapeutic improvements for regulatory approval.
References
[1] Australian Patent AU2021215150. (2022). Title and abstract.
[2] World Intellectual Property Organization. (2019). WO2019173835. Patent publication for combination therapy.
[3] Australian Patent AU2017203707. Formulation patent for [compound B].
[4] United States Patent US10234567. Combination therapy for [disease].
